Biblio

Found 19 results
[ Author(Desc)] Keyword Title Type Year
Filters: First Letter Of Last Name is K  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
K
B. K, Kaern, J., Simonsen, E., Piccart, M. J., G, H. Boes, Timmers, P., Roy, J. - A., Pecorelli, S., Stuart, G. C. E., James, K., Cassidy, J., and Kaye, S. B., Is cisplatin-taxol the standard treatment in advanced ovarian cancer., Eur.J.Can. , vol. 33, no. 8, 1997.
K. Katherine, Julia, B., Valerie, B., Oza, A. M., and Stephanie, L., Ovarian Cancer and BRCA1/2 Testing: Opportunities to improve clinical care and disease prevention , Frontiers in Oncology , vol. 6, no. 00119 , 2016.
N. Katsumata, Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., Sugiyama, T., Ochiai, K., and Group, J. Gynecologi, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, Lancet Oncol, vol. 14, pp. 1020-6, 2013.
N. Katsumata, Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., Ochiai, K., Noda, K., and Group, J. Gynecologi, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, vol. 374, pp. 1331-8, 2009.
S. B. Kaye and Group, S. Gynaecolog, The integration of docetaxel into first-line chemotherapy for ovarian cancer, Int J Gynecol Cancer, vol. 11 Suppl 1, pp. 31-3, 2001.
S. B. Kaye, Paul, J., Cassidy, J., Lewis, C. R., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Davis, J. A., Reed, N. Simon, Crawford, S. M., MacLean, A., Parkin, D., Sarkar, T. K., Kennedy, J., Symonds, R. P., and Group, S. Gynaecolog, Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group, J Clin Oncol, vol. 14, pp. 2113-9, 1996.
H. M. Keys, Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., Bell, J. G., and Group, G. Oncology, A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, vol. 92, pp. 744-51, 2004.
H. C. Kitchener and Trimble, E. L., Endometrial cancer state of the science meeting., Int J Gynecol Cancer, vol. 19, no. 1, pp. 134-40, 2009.
H. C. Kitchener, Management of endometrial cancer., Eur J Surg Oncol, vol. 32, no. 8, pp. 838-43, 2006.
H. C. Kitchener, Hoskins, W. J., Small, W., Thomas, G. M., Trimble, E. L., and Group, C. Cancer Con, The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report, Int J Gynecol Cancer, vol. 20, pp. 1092-100, 2010.
H. C. Kitchener, Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer., Cancer Treat Rev, vol. 31, no. 4, pp. 323-7, 2005.
S. Kommoss, du Bois, A., Ridder, R., Trunk, M. J., Schmidt, D., Pfisterer, J., Kommoss, F., and -OVAR, A. G. O., Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaek, Br J Cancer, vol. 96, pp. 306-13, 2007.
G. B. Kristensen, Vergote, I. B., Stuart, G. C. E., Del Campo, J. M., Kaern, J., Lopez, A. B., Eisenhauer, E., Åvall-Lundqvist, E., Ridderheim, M., Havsteen, H., Mirza, M. R., Scheistroen, M., and Vrdoljak, E., First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin., Int J Gynecol Cancer, vol. 13 Suppl 2, pp. 172-7, 2003.
G. B. Kristensen, Perren, T. J., Qian, W., Pfisterer, J., Ledermann, J. A., Joly, F., Carey, M. S., Beale, P., Cervantes, A., and Oza, A. M., Result of interim analysis of overall survival in the phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. , J Clin Oncol , vol. 29, no. suppl; abstr LBA5006, 2011.
K. Kudoh, Takano, M., Kouta, H., Kikuchi, R., Kita, T., Miyamoto, M., Watanabe, A., Kato, M., Goto, T., and Kikuchi, Y., Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers, Gynecol Oncol, vol. 122, pp. 233-7, 2011.
S. Kumagai, Sugiyama, T., Shoji, T., Michimae, H., Katsumata, N., Aoki, D., Terauchi, F., Jobo, T., Ochiai, K., and Yasuda, M., Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial., Int J Gynecol Cancer, vol. 21, no. 9, pp. 1585-91, 2011.
J. - E. Kurtz, Kaminsky, M. C., Floquet, A., Veillard, A. S., Kimmig, R., Dorum, A., Elit, L., Buck, M., Petru, E., Reed, N. Simon, Scambia, G., Varsellona, N., Brown, C., and Pujade-Lauraine, E., Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study., Ann Oncol, vol. 22, no. 11, p. 2423, 2011.
J. - E. Kurtz, Freyer, G., Joly, F., Gladieff, L., Kaminsky, M. C., Fabbro, M., Floquet, A., Hardy-Bessard, A. C., Raban, N., Ray-Coquard, I., Pujade-Lauraine, E., and France, G. I. N. E. C. O. Group, Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial, Anticancer Res, vol. 32, pp. 1045-9, 2012.
C. Kurzeder, L, Z., Eisenhauer, E., Vergote, I. B., du Bois, A., D, T., Y, W., JF, G., HW, H., B, R., LC, H., Bentley, J., Wagner, U., Plante, M., Kimmig, R., and Pfisterer, J., The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. , J Clin Oncol , vol. 29, no. suppl; abstr 5088, 2011.